文献速递消化系统肿瘤

高危肝损伤患者肝肿瘤的个体化自适应立体定向体部放疗:一项2期临床试验

Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

这项2期单臂试验自2010至2014年纳入90例既往接受过肝脏定向治疗、存在肝功能异常的肝内肿瘤患者,以吲哚菁绿15分钟滞留率(ICGR15)为肝功能直接生物标志物,用贝叶斯自适应模型在治疗中途个体化调整立体定向体部放疗(SBRT)计划。1年和2年局部控制率分别为99%(95%CI,97%-100%)和95%(95%CI,91%-99%),6个月时6例(7%)出现Child-Pugh评分下降2分。

要点

  • 90例患者中69例(77%)为肝细胞癌,62例(69%)有肝硬化,21例(23%)为Child-Pugh B级。
  • 62例(69%)完成全部5次照射,其中47例全剂量、15例因ICGR15升高而减量。
  • 1年和2年局部控制率分别为99%(95%CI,97%-100%)和95%(95%CI,91%-99%)。

核心结论

  • 基于肝功能直接生物标志物的个体化自适应治疗策略可在不牺牲局部控制率的同时实现高度安全性。
  • 个体化自适应放疗可能代表一种新的治疗范式,即剂量基于个体而非人群的治疗耐受性。

研究设计与样本

  • 2010至2014年在一家学术医学中心开展的大规模2期单臂临床试验,纳入90例既往接受过肝脏定向治疗的肝内肿瘤患者。
  • 所有患者均有至少1年的潜在随访时间。
  • 采用15分钟吲哚菁绿滞留率(ICGR15)作为肝功能直接生物标志物,并利用贝叶斯自适应模型在治疗中途个体化修改SBRT计划,以在全程治疗后维持肝功能。
  • 主要结局为局部控制,次要结局为安全性和总生存。
  • 试验注册号:clinicaltrials.gov NCT01522937。

主要发现

  • 患者年龄34至85岁,70%(63例)为男性。
  • 90例患者中69例(77%)为肝细胞癌,4例(4%)为肝内胆管癌,17例(19%)为转移性肿瘤,共治疗116个肿瘤。
  • 62例(69%)有肝硬化,21例(23%)为Child-Pugh(CP)B级;中位肿瘤大小3 cm;16例(18%)有门静脉受累。
  • 62例(69%)完成全部5次照射,其中47例全剂量、15例因ICGR15升高而减量。
  • 治疗耐受良好,未采用自适应时的并发症发生率低于预期:SBRT后6个月6例(7%)出现CP评分下降2分。

临床怎么用

  • 作者认为,基于肝功能直接生物标志物的个体化自适应治疗策略可用于同时实现高局部控制率和高安全性。
  • 作者认为,个体化自适应放疗可能代表一种新的治疗范式,即剂量基于个体而非人群的治疗耐受性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with preexisting liver dysfunction could benefit the most from personalized therapy for liver tumors to balance maximal tumor control and minimal risk of liver failure. We designed an individualized adaptive trial testing the hypothesis that adapting treatment based on change in liver function could optimize the therapeutic index for each patient. OBJECTIVE: To characterize the safety and efficacy of individualized adaptive stereotactic body radiotherapy (SRBT) for liver tumors in patients who have preexisting liver dysfunction. DESIGN, SETTING, AND PARTICIPANTS: From 2010 to 2014, 90 patients with intrahepatic cancer treated with prior liver-directed therapy were enrolled in this large phase 2, single-arm, clinical trial at an academic medical center. All patients had at least 1 year of potential follow-up. INTERVENTIONS: Using indocyanine green retention at 15 minutes (ICGR15) as a direct biomarker of liver function and a Bayesian adaptive model, planned SBRT was individually modified midway through the course of therapy to maintain liver function after the complete course. MAIN OUTCOMES AND MEASURES: The primary outcome was local control; the secondary outcome was safety and overall survival. RESULTS: Patients were 34 to 85 years of age, and 70% (63) were male. Ninety patients (69 [77%] with hepatocellular carcinoma, 4 [4%] with intrahepatic cholangiocarcinoma, and 17 [19%] with metastatic) received treatment to 116 tumors. Sixty-two patients (69%) had cirrhosis, 21 (23%) were Child-Pugh (CP) grade B. The median tumor size was 3 cm; 16 patients (18%) had portal vein involvement. Sixty-two (69%) received all 5 fractions (47 full dose, 15 dose-reduced owing to rising ICGR15). Treatment was well tolerated, with a lower than expected complication rate without adaptation: 6 (7%) experienced a 2-point decline in CP 6 months post-SBRT. The 1- and 2-year local control rates were 99% (95% CI, 97%-100%) and 95% (95% CI, 91%-99%), respectively. CONCLUSIONS AND RELEVANCE: We demonstrated that the treatment strategy of individualized adaptive therapy based on a direct biomarker of liver function can be used to achieve both high rates of local control and a high degree of safety without sacrificing either. Individualized adaptive radiotherapy may represent a new treatment paradigm in which dose is based on individual, rather than population-based, tolerance to treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01522937.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Feng M, Suresh K, Schipper MJ, et al. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol. 2018. PMID: 28796864. doi:10.1001/jamaoncol.2017.2303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。